BOTHELL, WA and VANCOUVER, March 28, 2013 /CNW/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that Scott Cormack, President and Chief Executive Officer, will provide a corporate presentation at the Future Leaders in the Biotech Industry Conference on Friday, April 5, 2013 at 9:30 a.m. ET at the Millennium Broadway Hotel in New York City.
A live audio webcast can be accessed through the Investor Relations page of the OncoGenex website at www.oncogenex.com. The webcast replay will be archived for 60 days.
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) have entered a global collaboration and license agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. OGX-427 is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development. More information is available at www.OncoGenex.com
SOURCE: OncoGenex Pharmaceuticals, Inc.
For further information:
Investor Relations Contact: